Objective To compare the efficacy and adverse effects of docetaxel and gemcitabine given at different times of the day for treating advanced non-small cell lung cancer(NSCLC).MethodsA total of 210 patients with pathologically diagnosed advanced NSCLC was equally divided into six groups of D1(intravenous infusion of docetaxel 40 mg/m2 at 8:00),D2(docetaxel 40 mg/m2 at 14:00),D3(docetaxel 40 mg/m2 at 20:00),G1(intravenous infusion of gemcitabine 1 g/m2 at 8:00),G2(gemcitabine 1 g/m2 at 14:00) and G3(gemcitabine 1 g/m2 at 20:00)...